Myomo (NYSEAMERICAN:MYO) Insider Harry Kovelman Sells 15,488 Shares

Myomo, Inc. (NYSEAMERICAN:MYO) insider Harry Kovelman sold 15,488 shares of the company’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $1.27, for a total value of $19,669.76. Following the completion of the transaction, the insider directly owned 90,245 shares in the company, valued at $114,611.15. This represents a 14.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Harry Kovelman also recently made the following trade(s):

• On Thursday, August 20th, Harry Kovelman sold 17,250 shares of Myomo stock. The stock was sold at an average price of $1.73, for a total value of $29,842.50.

Myomo Stock Performance

Shares of Myomo stock remained flat at $1.30 on Monday. The stock had a trading volume of 292,957 shares, compared to its average volume of 593,168. The business has a fifty day simple moving average of $1.29 and a two-hundred day simple moving average of $1.04. The stock has a market cap of $51.49 million, a price-to-earnings ratio of -3.82 and a beta of 1.50. The company has a debt-to-equity ratio of 1.98, a current ratio of 2.31 and a quick ratio of 2.01. Myomo, Inc. has a 12 month low of $0.60 and a 12 month high of $1.89.

Myomo (NYSEAMERICAN:MYO) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The business had revenue of $11.70 million during the quarter, compared to analyst estimates of $10.35 million. Myomo had a negative return on equity of 138.85% and a negative net margin of 33.53%. On average, equities analysts anticipate that Myomo, Inc. will post -0.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets boosted their price target on shares of Myomo from $9.50 to $10.00 and gave the company a “buy” rating in a report on Monday, June 8th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $10.00.

Institutional Investors Weigh In On Myomo

An institutional investor recently bought a new stake in Myomo stock. Prescott Group Capital Management L.L.C. bought a new stake in Myomo, Inc. (NYSEAMERICAN:MYO) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 185,433 shares of the company’s stock, valued at approximately $169,000. Prescott Group Capital Management L.L.C. owned 0.48% of Myomo at the end of the most recent reporting period. 44.99% of the stock is owned by hedge funds and other institutional investors.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.